21 November 2021
Australia included Takhzyro in PBS scheme
Australia included Takhzyro (lanadelumab) in the Pharmaceutical Benefits Scheme (PBS) for patients with hereditary angioedema.
Hereditary angioedema is a rare disease affecting 1 in 50,000 patients. It is because of the defect in C1-Inhibitor gene, there by increasing the bradykinin in the bloodstream. The first attack occurs in the pediatrics and adoloscents, causing odema in hands, feet, face and airway.
Takhzyro decreases the bradykinin in the bloodstream. It is expected to help 100 patients/year in Australia.
Pharmaceutical Benefits Advisory Committee has made the recommendation to include Takhzyro (lanadelumab) in the PBS.
20 October 2019
Vertex’s Symdeko and Orkambi is now reimbursed in Australia
Vertex’s Symdeko (tezacaftor/ivacaftor and ivacaftor) and Orkambi (lumacaftor/ivacaftor) are now reimbursed Australia.
Symdeko is approved in patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have one copy of the F508del mutation and another responsive residual function (RF) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Orkambi is now reimbursed in children with CF ages 2 to 5 who have two copies of the F508del mutation in the CFTR gene. The product already reimbursed for patients aged more than 6 years since October 2018.
The company in its press released mentioned that the product is reimbursed in seventeen countries.